Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Acta Derm Venereol ; 103: adv00868, 2023 Feb 15.
Article in English | MEDLINE | ID: mdl-36789756

ABSTRACT

Dandruff is a common scalp disorder with multiple microbial and host-related factors contributing to its aetiology, including alterations in scalp sebum. Despite existing evidence that the yeast Malassezia restricta plays a key role in the onset of dandruff, the interplay of these factors is poorly understood. Recently, squalene monohydroperoxide and malondialdehyde were established as biomarkers of dandruff-afflicted scalp, highlighting the role of sebum lipoperoxidation in the triggering and maintenance of dandruff, although its mechanism of action is unknown. The current study provides evidence that M. restricta mediates sebum peroxidation, leading to production of squalene monohydroperoxide and malondialdehyde. Furthermore, in vitro data show that these lipoperoxidation products act on epidermal cells and alter the skin barrier. These results support the role of Malassezia restricta-induced lipoperoxides as triggers of dandruff, which suggests that blocking their production could be a novel anti-dandruff treatment approach.


Subject(s)
Dandruff , Malassezia , Humans , Dandruff/drug therapy , Dandruff/etiology , Malondialdehyde
2.
Eur J Pharm Sci ; 173: 106161, 2022 Jun 01.
Article in English | MEDLINE | ID: mdl-35248735

ABSTRACT

Klebsiella pneumoniae is one of the main causes of hospital-acquired infections. Its rate of antimicrobial resistance is rapidly increasing, while there are no licensed human vaccines against it. A novel therapeutic approach involves modulation of the host immune response combined with antibiotic treatment. One of the approaches to immunomodulation can be the use of antibodies (Abs) in a specific technological form of high dilutions (hd). The aim of the study was to assess whether hd-Abs could affect the antibacterial activity of AMC against a bacterial strain resistant to it. The study was performed on an in vivo model of K. pneumoniae BAA-1705 multiresistant strain lethal infection in neutropenic RjOrl:Swiss mice. The efficacy of hd-Abs combined with AMC was assessed based on survival and lung bacterial burden. Additionally, we evaluated the direct effect of the drugs on the growth of bacteria in vitro. hd-Abs in combination with AMC increased survival of mice infected with K. pneumoniae up to 50%, whereas all animals in the AMC group died. Hd-Abs had no direct effect on K. pneumoniae sensitivity to AMC in vitro. The survival rate in mice treated with hd-Abs combined with AMC was comparable to that in animals treated with the reference drug gentamicin. Thus, hd-Abs increased the antibacterial activity of AMC against the strain resistant to it. The mechanism of action of hd-Abs remains to be elucidated in future studies.


Subject(s)
Cross Infection , Klebsiella Infections , Animals , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Klebsiella Infections/drug therapy , Klebsiella Infections/microbiology , Klebsiella pneumoniae , Mice , Microbial Sensitivity Tests
3.
PLoS Pathog ; 17(2): e1009310, 2021 02.
Article in English | MEDLINE | ID: mdl-33630958

ABSTRACT

Urinary tract infections (UTIs) are among the most common outpatient infections, with a lifetime incidence of around 60% in women. We analysed urine samples from 223 patients with community-acquired UTIs and report the presence of the cleavage product released during the synthesis of colibactin, a bacterial genotoxin, in 55 of the samples examined. Uropathogenic Escherichia coli strains isolated from these patients, as well as the archetypal E. coli strain UTI89, were found to produce colibactin. In a murine model of UTI, the machinery producing colibactin was expressed during the early hours of the infection, when intracellular bacterial communities form. We observed extensive DNA damage both in umbrella and bladder progenitor cells. To the best of our knowledge this is the first report of colibactin production in UTIs in humans and its genotoxicity in bladder cells.


Subject(s)
DNA Damage , Escherichia coli Infections/pathology , Peptides/metabolism , Polyketides/metabolism , Urinary Bladder/pathology , Urinary Tract Infections/pathology , Uropathogenic Escherichia coli/isolation & purification , Aged , Animals , Escherichia coli Infections/genetics , Escherichia coli Infections/microbiology , Female , Humans , Male , Mice , Mice, Inbred C3H , Mutagens/metabolism , Urinary Bladder/metabolism , Urinary Bladder/microbiology , Urinary Tract Infections/genetics , Urinary Tract Infections/microbiology
4.
Gut ; 70(6): 1078-1087, 2021 06.
Article in English | MEDLINE | ID: mdl-33020209

ABSTRACT

OBJECTIVE: The enteric nervous system (ENS) plays a key role in controlling the gut-brain axis under normal and pathological conditions, such as type 2 diabetes. The discovery of intestinal actors, such as enterosynes, able to modulate the ENS-induced duodenal contraction is considered an innovative approach. Among all the intestinal factors, the understanding of the role of gut microbes in controlling glycaemia is still developed. We studied whether the modulation of gut microbiota by prebiotics could permit the identification of novel enterosynes. DESIGN: We measured the effects of prebiotics on the production of bioactive lipids in the intestine and tested the identified lipid on ENS-induced contraction and glucose metabolism. Then, we studied the signalling pathways involved and compared the results obtained in mice to human. RESULTS: We found that modulating the gut microbiota with prebiotics modifies the actions of enteric neurons, thereby controlling duodenal contraction and subsequently attenuating hyperglycaemia in diabetic mice. We discovered that the signalling pathway involved in these effects depends on the synthesis of a bioactive lipid 12-hydroxyeicosatetraenoic acid (12-HETE) and the presence of mu-opioid receptors (MOR) on enteric neurons. Using pharmacological approaches, we demonstrated the key role of the MOR receptors and proliferator-activated receptor γ for the effects of 12-HETE. These findings are supported by human data showing a decreased expression of the proenkephalin and MOR messanger RNAs in the duodenum of patients with diabetic. CONCLUSIONS: Using a prebiotic approach, we identified enkephalin and 12-HETE as new enterosynes with potential real beneficial and safety impact in diabetic human.


Subject(s)
12-Hydroxy-5,8,10,14-eicosatetraenoic Acid/biosynthesis , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/physiopathology , Duodenum/physiology , Enteric Nervous System/physiology , Prebiotics , Receptors, Opioid, mu/metabolism , 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid/pharmacology , Adult , Aged , Animals , Brain-Gut Axis , Diabetes Mellitus, Experimental/physiopathology , Duodenum/innervation , Enkephalins/genetics , Enkephalins/metabolism , Enteric Nervous System/drug effects , Gastrointestinal Microbiome , Glucose Tolerance Test , Humans , Isotonic Contraction/drug effects , Male , Mice , Middle Aged , Muscle, Smooth/physiology , Neurons/physiology , Nitric Oxide Synthase Type I/genetics , Nitric Oxide Synthase Type I/metabolism , Oligosaccharides/pharmacology , PPAR gamma/metabolism , Protein Precursors/genetics , Protein Precursors/metabolism , RNA, Messenger/metabolism , Receptors, Opioid, mu/genetics , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL